Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe
Shots:
- Under the agreement, Ionis gains right for the preclinical and clinical development of donidalorsen while Otsuka holds exclusive commercialization rights in the EU along with its regulatory filings
- Ionis is eligible for a $65M upfront payment, milestone payments tied to regulatory and sales targets, and tiered royalties (20% to 30% based on annual net sales) for donidalorsen. It anticipates launching donidalorsen in the US upon approval, independently
- Additionally, Ionis revealed 2yr. P-II open-label extension (OLE) study data that indicated a 96% overall sustained mean reduction in baseline HAE attack rates with donidalorsen. The P-III study data is anticipated in H1’24
Ref: Ionis | Image: Ionis
Related News:- Ionis Pharmaceuticals Reports the Results for Donidalorsen in P-II Trial to Treat Type 1 and Type 2 Hereditary Angioedema
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
